Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated donor-derived anti-CD19 CAR-T cells in patients with recurrent or persistent B-cell malignancies after allogeneic stem cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Donor-derived anti-CD19 CAR-T cells (donor-derived anti-CD19 chimeric antigen receptor T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, B-cell, Lymphoma, Hodgkins | Phase 1 | Status: COMPLETED